ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott following the release of new positive data relating to its CTX cell therapy candidate which has been published in the peer-reviewed scientific journal Stem Cells.
He says the new data shows for the first time that ReNeuron's CTX human neural stem cell line can 'rescue deficits' associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.
